Delta-like ligand 3 (DLL3) inhibitors like rovalpituzumab tesirine have shown potential in preclinical studies targeting DLL3 expression in SCLC but requires further validation in clinical trials [44]. Here, DLL3 is linked to small cell lung carcinoma.